[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"itch\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:itch":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,85,113,135,150,167,189,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100491375","establishment-of-a-patient-library-in-patients-with-pruritus-sine-materia-100491375",false,"NCT05678309","Establishment of a Patient Library in Patients With Pruritus Sine Materia","PRURITHEQUE","Inclusion Criteria:\n\n* Diagnosis of pruritus sine materia\n* Collection of consent\n* Adult\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study","ALL","18 Years","99 Years",{"count":20,"type":21},175,"ESTIMATED","5 Years","OBSERVATIONAL","Very little is currently known about the pathophysiology of pruritus sine materia according to the etiology. The creation of this cohort should make it possible to improve our clinical and biological knowledge according to the etiology, by collecting blood, skin, feces, and clinical data.",[26,27,28],"Pruritus","Chronic Pruritus","Itch","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2023-06-16",{"date":37,"type":21},"2033-06",{"name":39,"class":40},"University Hospital, Brest","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100637488","efficacy-and-safety-of-ha35-gel-for-ultra-rapid-skin-pruritus-relief-100637488","NCT07580911","Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Diverse Etiology Skin Pruritus","HA35-ITCH","Inclusion Criteria:\n\n* Age 18-65 years, male or female\n* Moderate-to-severe skin pruritus (NRS ≥6) due to eczema, neurodermatitis, insect bites, urticaria, or postoperative wound itch\n* Able to understand and complete NRS assessments independently\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Topical corticosteroid\u002Fantihistamine use within 2 weeks\n* Infected, broken, or exudative skin lesions at the application site\n* Known hypersensitivity to hyaluronan or gel components\n* Severe systemic disease or immune dysfunction\n* Pregnant or lactating women","65 Years",{"count":52,"type":21},30,"INTERVENTIONAL",[55],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus from diverse etiologies (eczema, neurodermatitis, insect bites, urticaria, postoperative wound itch). Eligible participants will receive a single topical application of HA35 gel. The primary objective is to assess pruritus relief at 10 seconds, 45 minutes, 8 hours, 12 hours, and 24 hours post-application. Safety and local skin tolerability will be evaluated throughout the observation period. This is a minimal-risk, non-pharmacological, non-invasive intervention.",[58,28,59,60,61,62,63],"Skin Pruritus","Eczema Itch","Neurodermatitis","Insect Bite Itch","Urticaria","Postoperative Wound Pruritus",[65,66,67,68,58,69,70,71,72,73],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Itch Relief","Ultra-Rapid Relief","Anti-Pruritus","Non-Steroidal","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-05",{"date":77,"type":33},"2026-05-12",{"date":79,"type":21},"2026-06-20",{"date":81,"type":21},"2026-08-20",{"name":83,"class":84},"Nakhia Impex LLC","INDUSTRY",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":53,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100636048","phase-4-obtaining-descriptive-classifications-of-pruritus-and-assessing-change-in-pruritus-over-time-in-atopic-dermatitis-patients-using-topical-roflumilast-cream-100636048","NCT07560618","Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.","A Phase 4, Open Label Study to Assess Descriptive Classification of Pruritus Over Time With Roflumilast 0.15% Cream in Patients With Atopic Dermatitis","Inclusion Criteria:\n\n1. Male or female subjects aged 12 years or older\n2. Participants and\u002For legal guardians are legally competent to sign and give informed consent.\n3. Clinically confirmed diagnosis of active mild to moderate AD according to Hanifin and Rajka criteria (1980).\n4. History of AD for at least 6 months as determined by the Investigator using information from the subject's medical chart, from the subject's physician, or through subject\u002Fcaregiver interview. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening\n5. At least 3 months of chronic pruritus related to AD before the screening visit.\n6. EASI Score ≥5 at Baseline. EASI is evaluated for the entire body except the scalp, palms, and soles.\n7. vIGA-AD score of 'Mild' (2') or 'Moderate' (3') at Baseline. The vIGA-AD is evaluated for the entire body except the scalp, palms, and soles.\n8. Has AD involvement of ≥3% BSA (excluding the scalp, palms, soles) at Baseline.\n9. Participants must have access to a device and be willing to download the ExpiWell app and able to complete the associated questionnaires once daily at approximately the same time each day throughout participation in the study.\n10. Prior to the first application of study drug, participant has a baseline WI-NRS (24-hour recall period) and mItch-NRS score ≥ 4.0.\n11. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening and Baseline\u002FDay 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial. The use of abstinence as a contraceptive measure is acceptable if this is a consistent part of a lifestyle choice and an acceptable backup method has been identified if the subject becomes sexually active.\n12. Females of non-childbearing potential should be post-menopausal with spontaneous amenorrhea for at least 12 months (post-menopausal status should be confirmed with FSH testing) or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral oophorectomy, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy).\n13. In good health as judged by the Investigator, based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)\u002Flegal guardian(s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.\n\nExclusion Criteria:\n\n1. Subjects with any medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.\n2. Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments.\n3. Participant had significant flares or unstable course in AD (i.e., condition worsened significantly or required significant change in medications, as per medical judgment) in the previous 4 weeks before screening or any consistent requirement for high potency topical steroids to manage AD signs or symptoms.\n4. Participant has significant active systemic or localized infection, like clinically infected AD, or has used antibiotics (systemic or topical), antifungal or antiviral agents within 2 weeks prior to the run-in period.\n5. Participant with a history or presence of a condition that, in the opinion of the investigator, would interfere with the study assessments (e.g., generalized erythroderma, Netherton syndrome, psoriasis, or any skin condition other than AD that may risk inducing a pruritus flare\u002Fworsening).\n6. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline\u002FDay 1 and during the study.\n7. Participants have tattoos, scratches, open sores, excessive hair, or skin damage that, in the opinion of the investigator, may interfere with study evaluations.\n8. Subjects with known genetic dermatological conditions that overlap with AD, such as Netherton syndrome.\n9. Known allergies to roflumilast or to the excipients in Roflumilast cream (petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetylstearyl alcohol, dicetyl phosphase and ceteth-10 phosphate).\n10. Participant has a clearly defined etiology for pruritus other than AD, including but not limited to urticaria, psoriasis, or other nonatopic dermatologic conditions; hepatic or renal disease; psychogenic pruritus; drug reaction; uncontrolled hyperthyroidism; and infection.\n11. Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline\u002F Day 1.\n12. History of severe depression, suicidal ideation or behavior at Baseline\u002FScreening indicative of suicidal ideation or behavior, whether lifetime or recent\u002Fcurrent.\n13. Subjects currently undergoing allergy testing (eg, food allergy testing or skin prick testing), patch testing, food challenges, or allergy desensitization, or plan to do so during the study.\n14. Subjects with any serious medical condition (eg, uncontrolled hypo- or hyper-thyroidism) or clinically significant laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.\n15. Previous treatment with Roflumilast cream or foam (any potency) or current Roflumilast use for any indication at the baseline visit that would be expected to continue during the trial.\n16. Subjects with a history of major surgery within 4 weeks prior to Baseline\u002FDay 1 or subjects who have major surgery planned during the study.\n17. Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.\n18. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.\n19. Subjects with known or suspected severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C) as determined by the clinical investigator based upon subject's medical history and physical exam.","12 Years",{"count":94,"type":21},40,[96],"PHASE4","This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.",[99,100],"ITCH","Atopic Dermatitis",[102,28,26,100,103],"Eczema","Topical","2026-04-23",{"date":106,"type":33},"2026-05-01",{"date":108,"type":21},"2026-04",{"date":110,"type":21},"2027-08",{"name":112,"class":84},"Integrative Skin Science and Research",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":53,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":41},"100612554","mechanisms-underlying-the-nocibo-effect-of-contagious-itch-in-both-histaminergic-and-nonhistaminergic-itch-100612554","NCT07255092","Mechanisms Underlying the Nocibo Effect of Contagious Itch. in Both Histaminergic and Nonhistaminergic Itch","Pain and Itch Neuromodulation: Effects of Offset Analgesia, Placebo, and Nocebo and Topographical Distribution of Itch and Pain Receptors","Inclusion Criteria:\n\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, immunological, musculoskeletal, cardiac disorder or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers\n* Skin diseases\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain and itch\n* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)\n* Contraindications to capsaicin, including intolerance to chili or burns or wounds at the application site\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",true,"60 Years",{"count":52,"type":21},[55],"The study consists of one experimental session of approximately 1½ hours. The participant will fill in a series of questionnaires about how you perceive itch and pain, and about some traits of your personality, such as depression, anxiety and stress. Afterwards, three areas will be selected on each forearm of the subjects.\n\nTwo areas will be treated with histamine, two with cowhage, and two with vehicle. One application of each substance will be conducted including the contagious itch component. During the 10 minutes of the application of the pruritogens, itch and pain will be continuously monitored using a VAS scale.",[99],"2025-11-27",{"date":128,"type":33},"2025-12-04",{"date":130,"type":21},"2025-12-01",{"date":132,"type":21},"2028-12-31",{"name":134,"class":40},"Aalborg University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":118,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":120,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":141,"targetDuration":4,"studyType":53,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":41},"100611985","mechanisms-underlying-the-placebo-effect-in-both-histaminergic-and-non-histaminergic-itch-100611985","NCT07247695","Mechanisms Underlying the Placebo Effect in Both Histaminergic and Non-histaminergic Itch","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, immunological, musculoskeletal, cardiac disorder or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers\n* Skin diseases\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain and itch\n* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)\n* Contraindications to capsaicin, including intolerance to chili or burns or wounds at the application site\n* The subject is assessed as unable to engage in the necessary cooperation required by the study",{"count":52,"type":21},[55],"The study consists of one experimental session of approximately 1½ hours. The participant will fill in a series of questionnaires about how you perceive itch and pain, and about some traits of your personality, such as depression, anxiety and stress. Afterwards, two areas will be selected on each forearm of the subjects. The four areas will be treated with the same vehicle cream for 20 minutes, in order to test the placebo effect. At the end of the cream application, two areas will be randomly treated with histamine while cowhage will be applied on the other two areas. During the 10 minutes of the application of the pruritogens, itch and pain will be continuously monitored using a Visual Analog Scale.",[99],{"date":128,"type":33},{"date":147,"type":33},"2025-11-03",{"date":132,"type":21},{"name":134,"class":40},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":118,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":120,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":155,"targetDuration":4,"studyType":53,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":166,"locationsCount":41},"100602397","topographical-distribution-of-itch-and-pain-receptors-100602397","NCT07122973","Topographical Distribution of Itch and Pain Receptors",{"count":52,"type":21},[55],"The experiment consists of three experimental sessions conducted on three consecutive days.\n\nIn all experimental sessions, the participant will fill in a series of questionnaires about how you perceive itch and pain, and about some traits of your personality, such as depression, anxiety and stress.\n\nIn the first session, we will mark six test areas in your face (three on each side on jaw, cheek, and temple, respectively). Thent a series of measure-ments in each test area will be conducted:measurement of the blood flow in the skin and sensitivity tests to pressure, pinprick and stroke with a brush.\n\nIn the second session, histamine will be applied in one side of the face. On the other side, cowhage spicules will be applied. After 10 minutes, all the tests will be conducted again.\n\nThe third session will be identical to the second. However, instead of histamine and spicules, patches containing capsaicin will be applied. In the other side, we will apply patches with placebo (i.e., a non-active patch). After 20 minutes all the tests will be conducted again.",[159,28],"Pain","2025-09-30",{"date":162,"type":33},"2025-10-01",{"date":164,"type":33},"2025-09-17",{"date":132,"type":21},{"name":134,"class":40},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":120,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":175,"targetDuration":4,"studyType":53,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100554778","role-of-interleukin-13-pathways-on-pain-and-itch-sensitivity-100554778","NCT06503510","Role of Interleukin-13 Pathways on Pain and Itch Sensitivity","The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers","IL-13","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other drugs\n* Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)\n* Moles, wounds, scars, or tattoos in the area to be treated or tested\n* Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).\n* Use of systemic and topical corticosteroids\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)\n* Lack of ability to cooperate",{"count":176,"type":21},20,[55],"Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.",[28],"2025-05-30",{"date":182,"type":33},"2025-06-04",{"date":184,"type":33},"2025-01-06",{"date":186,"type":21},"2026-12-31",{"name":134,"class":40},3,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":53,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":41},"100576630","reducing-itch-with-hypnosis-and-virtual-reality-100576630","NCT06787794","Reducing Itch With Hypnosis and Virtual Reality","The Effectiveness of Virtual Reality-assisted Hypnosis in Reducing Itch: a Proof-of-concept Study","VRITCH","Inclusion Criteria:\n\n* Participants must be adults (aged 18-80 years)\n* Participants must have been suffering from chronic pruritus of any origin for at least 1 year prior to inclusion in this study\n* Participants must have been seen by a physician for the itch\n* Participants must experience psychological and\u002For functional impairment due to the itch despite standard medical treatment.\n* Participants must speak and understand Dutch and be able to complete questionnaires.\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidities irrelated to their itch condition such as psychosis or severe clinical depression or anxiety disorder (anxiety and depressive symptoms in itself are common in individuals with chronic symptoms and therefore no reason for exclusion);\n* History of seizures;\n* History of severe migraine;\n* Severe susceptibility to motion sickness;\n* Balance problems;\n* Face, head, or neck injury;\n* Visual or audiological impairment;\n* Pacemaker, defibrillator and\u002For other electronic (implantable) device of vital importance;\n* Pregnancy;\n* Lactation;\n* Participation in another interventional itch study.","80 Years",{"count":52,"type":21},[55],"Chronic itch is a disabling condition with currently limited treatment options. Virtual reality (VR) is a relatively new approach that provides immersion in another environment and has been shown to have a temporary itch mitigating potential. Hypnosis, which is a state of relaxation, has been successfully applied with more long-term treatment effects in the specific case of itch as a result of severe atopic dermatitis. However, hypnosis tends to depend on an individual's susceptibility, or ease, to come into a hypnotic state. A combination of VR and hypnosis (VRH) has been put forward since it may combine the longer lasting effects of hypnosis with VR making the hypnosis more accessible by facilitating imagination. Even though VRH is a promising avenue, it has never been investigated in the context of itch. In this randomized controlled trial, comparing a VRH treatment with a waiting list control group after 6 sessions and at follow-up, it is aimed to assess the effectiveness of VRH in reducing itch along with its psychological burden in adult individuals with therapy-resistant disabling itch.",[99,26],[27,203,204,205,206,207,208],"Chronic Itch","Therapy resistant","Virtual Reality (VR)","Hypnosis","Relaxation","Distraction","2025-03-24",{"date":211,"type":33},"2025-03-25",{"date":213,"type":33},"2025-01-31",{"date":186,"type":21},{"name":216,"class":40},"Universiteit Leiden",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":120,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":224,"targetDuration":4,"studyType":53,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":235},"100554779","the-effects-of-performing-a-motor-imagery-task-on-cortical-excitability-during-acute-experimental-muscle-pain-and-acute-itch-100554779","NCT06503523","The Effects of Performing a Motor Imagery Task on Cortical Excitability During Acute Experimental Muscle Pain and Acute Itch","Investigation of the Neurophysiological and Psychological Aspects of Itch","Inclusion Criteria:\n\n* Healthy men and women\n* 18-60 years\n* Speak and understand English\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Drug addiction defined as any use of cannabis, opioids, or other addictive drugs\n* Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder (e.g., heart stroke), or psychiatric diagnoses (e.g. depression) that may affect the results\n* Current use of medications that may affect the trial, such as antihistamines, antipsychotics, and painkillers, as well as systemic or topical steroids\n* Skin diseases (e.g., atopic dermatitis, pruritus nodularis, eczema, psoriasis)\n* Moles, scars, or tattoos in the area to be treated or tested.\n* Consumption of alcohol or painkillers 24 hours before the study days and between these\n* Acute or chronic pain\n* Unable to pass the \"Transcranial Magnetic Stimulation Adult Safety Screen\" (subproject 1 and 2)\n* Contraindications to transcranial magnetic stimulation (TMS) application (history of epilepsy, metal implants in head or jaw, etc.)\n* Presence of implanted hearing aids or metal implants on the face, including permanent makeup or tattoos\n* Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)\n* Lack of ability to cooperate",{"count":52,"type":21},[55],"The aim of this project is to determine the effects of performing a motor imagery task on cortical excitability during acute experimental muscle pain (induced by hypertonic saline), acute histaminergic itch (induced by histamine), and non-histaminergic itch stimulation (triggered by Cowhage). We hypothesize that motor imagery will counteract the alterations in cortical excitability observed during experimental muscle pain and both itch models.",[28,159],"2024-11-20",{"date":230,"type":33},"2024-11-22",{"date":232,"type":33},"2024-10-01",{"date":186,"type":21},{"name":134,"class":40},2]